Drugs / MAS825
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04665154 | Jun 2019 → Aug 2022 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 26 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT07748624 | Oct 2026 → Dec 2028 expected | VEXAS syndrome | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT07203001 | Nov 2025 → Apr 2027 expected | autoinflammatory syndrome | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT06097663 | Feb → Oct 2024 | clonal hematopoiesis of indeterminate potential, coronary artery disorder | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT04641442 | Dec 2020 → Oct 2025 overdue | periodic fever-infantile enterocolitis-autoinflammatory syndrome | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04382651 | Jun 2020 → Jan 2021 | pneumonia | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT03827798 | Feb 2019 → Dec 2024 overdue | hidradenitis suppurativa | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06309823 | Feb 2023 → Jan 2024 | X-linked lymphoproliferative disease due to XIAP deficiency | The Hospital for Sick Children | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAS825 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04641442 ↗ |
| Known as | Arumakimig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07748624 ↗ |
| Action | Inhibit | “MAS825, a bispecific IL-1β/IL-18 monoclonal antibody, could improve clinical outcomes in COVID-19 pneumonia by reducing inflammasome-mediated inflammation.” PMID 37338154 ↗ Oct 2023 |
| Modality | Monoclonal antibody | “MAS825, a bispecific IL-1β/IL-18 monoclonal antibody” PMID 37338154 ↗ Oct 2023 |
| Route | Subcutaneous | “MAS825 300 mg administered s.c.” NCT03827798 ↗ |